ERK5 inhibitor XMD17-109 inhibits glioma progression by down-regulating ITPRIP expression
10.3969/j.issn.1671-8348.2023.23.005
- VernacularTitle:ERK5抑制剂XMD17-109通过下调ITPRIP表达抑制胶质瘤进展
- Author:
Xinwen WANG
1
,
2
;
Changchun CAO
;
Liang ZHU
;
Yu DU
;
Zengxian SUN
Author Information
1. 徐州医科大学附属连云港医院药学部,江苏连云港 222061
2. 徐州医科大学淮安临床学院药学部,江苏淮安 223300
- Keywords:
extracellular signal-regulated kinase 5;
inositol 1,4,5-trisphosphate receptor-interacting protein;
XMD17-109;
glioma;
inhibitor
- From:
Chongqing Medicine
2023;52(23):3546-3553
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effect of XMD17-109 on the viability of glioma cells and its molecular mechanism based on extracellular signal-regulated kinase 5(ERK5)/inositol 1,4,5-trisphosphate receptor-interacting protein(ITPRIP)signaling pathway.Methods U251 glioma cells were routinely cul-tured,and ERK5 activity was inhibited by XMD17-109.ERK5 knockdown and ERK5 overexpression models were constructed by transfection of RNA fragments and plasmids,respectively.Cells were divided divided into the XMD17-109 group,the Control group,the siERK5 group,the siNC group,siERK5-OE group,the Vector group,the ERK5-OE+XMD17-109 group and the Vector+XMD17-109 group.The cell viability was detected by CCK-8,scratch and flow cytometry experiments and so on.The mRNA and protein expression levels of ERK5 and ITPRIP were detected by reverse transcription-quantitative real time PCR(RT-qPCR)and West-ern blot.Results Compared with the Control group,the cell viability of the XMD17-109 group decreased,and the expression level of ITPRIP decreased(P＜0.05).Compared with the siNC group,the cell viability of the siERK5 group was decreased,and the expression level of ITPRIP was decreased(P＜0.05).Compared with the Vector group,the cell viability of the ERK5-OE group was enhanced,and the expression level of ITPRIP was increased(P＜0.05).Compared the with Vector+XMD17-109 group,the cell viability of the ERK5-OE+XMD17-109 group was enhanced,and the expression level of ITPRIP was increased(P＜0.05).Conclusion XMD17-109 can inhibit the viability of glioma cells by inhibiting ERK5/ITPRIP signaling pathway,which is expected to be a potential drug for glioma treatment.
